Update shared on 29 Nov 2025
Fair value Increased 2.09%Analysts have modestly raised their price target for WuXi Biologics (Cayman), increasing it from ¥38.59 to ¥39.39. This change reflects small upward adjustments to fair value estimates based on updated financial projections.
What's in the News
- Launched TrueSite TI, a fourth-generation targeted integration-based CHO cell line platform to accelerate biologics development, enhance product quality, and ensure consistent scalability for antibody and complex protein therapies (Key Developments).
- TrueSite TI offers stable protein expression after 60 generations and significantly shortens IND timelines. It has strong applicability for bispecific antibodies, Fc-fusion proteins, and Fab fragments (Key Developments).
- Introduced the "WuXi Biologics Green CRDMO White Paper," which outlines sustainable end-to-end solutions for biologics and showcases 242 energy-saving cases across 25 technology categories (Key Developments).
- WuXi Biologics has earned multiple ESG recognitions, including an MSCI AAA Rating, EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices and Hang Seng ESG 50 Index (Key Developments).
- Recently adopted new climate targets approved by SBTi and achieved measurable ESG benefits in over 90% of completed Kaizen projects in 2024 (Key Developments).
Valuation Changes
- The Fair Value Estimate has risen slightly from HK$38.59 to HK$39.39.
- The Discount Rate increased marginally from 7.98% to 8.03%.
- The Revenue Growth projection edged up from 16.11% to 16.12%.
- The Net Profit Margin forecast saw a slight rise from 21.46% to 21.47%.
- The future Price-to-Earnings (P/E) ratio estimate increased modestly from 26.08x to 26.51x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.